Sayantani Bhattacharya Sindher, MD
Allergy & Immunology · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 13
- 2 carriers
- Office
- 1
Offices
1 location
Plans that list them
13 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Sindher’s office at (650) 497-8000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
13 of 13 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A144981 · Current
Licensed to practise in California · since 2016 · expires 2028-01-31 · State University of New York, Downstate Medical Center College of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Allergy and Immunology - Allergy and Immunology
- American Board of Pediatrics - Pediatrics
Drugs they prescribed that Part D paid
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their 31 Part D prescriptions in 2020. Too few prescriptions to judge: with under about 50 a year, a handful of patients can swing this share.
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
Year by year
| 2020 | 31 | None | 0% (0) | None | $3,684 |
| 2019 | 94 | 13 | 0% (0) | 34% | $8,526 |
| 2018 | 118 | 25 | 0% (0) | 20% | $6,679 |
| 2017 | 23 | None | 0% (0) | None | $1,089 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2019: 2 drugs
| Azelastine | 36 | $1,593 | $44 |
| Fluticasone Propionate | 21 | $486 | $23 |
2018: 4 drugs
| Azelastine | 24 | $1,362 | $57 |
| Fluticasone Propionate | 25 | $335 | $13 |
| Montelukast | 15 | $167 | $11 |
| Ranitidine | 16 | $105 | $7 |
Money from drug and device companies
$12,022 in 2025
| 2025 | 6 | 15 | $9,835 | $12,022 |
| 2024 | 1 | 10 | $13,800 | $15,011 |
| 2023 | 2 | 3 | $600 | $822 |
| 2022 | 3 | 4 | $2,795 | $2,854 |
| 2020 | 1 | 1 | $389 | $389 |
| 2019 | 1 | 1 | None | $22 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Genentech USA | Xolair | $7,433 | 8 payments
|
| kaleo | Auvi-Q | $4,343 | 3 payments
|
| Aquestive Therapeutics | Libervant | $119 | 1 payment
|
| ALK-Abello | None | $55 | 1 payment
|
| Greer Laboratories | Palforzia | $53 | 1 payment
|
| Kyowa Kirin | None | $20 | 1 payment
|
See all 15 published payments
| kaleo | Consulting · 2025-12-15 | Auvi-Q | $1,950 |
| Genentech USA | Meals · 2025-12-06 | Xolair | $35 |
| Genentech USA | Meals · 2025-12-06 | Xolair | $210 |
| Genentech USA | Meals · 2025-12-06 | Xolair | $138 |
| Genentech USA | Travel · 2025-12-06 | Xolair | $635 |
| Genentech USA | Meals · 2025-12-06 | Xolair | $102 |
| Genentech USA | Travel · 2025-12-06 | Xolair | $525 |
| Genentech USA | Meals · 2025-12-06 | Xolair | $178 |
| Genentech USA | Consulting · 2025-12-06 | Xolair | $5,610 |
| kaleo | Consulting · 2025-11-06 | Auvi-Q | $2,275 |
| kaleo | Meals · 2025-11-06 | Auvi-Q | $118 |
| Aquestive Therapeutics | Meals · 2025-11-06 | Libervant | $119 |
| Kyowa Kirin | Meals · 2025-05-20 | None | $20 |
| ALK-Abello | Meals · 2025-03-01 | None | $55 |
| Greer Laboratories | Meals · 2025-02-27 | Palforzia | $53 |
See earlier years (2024, 2023, 2022, 2020, 2019)
2024: $15,011
| Genentech USA | Xolair | $15,011 | 10 payments
|
2023: $822
| Genentech USA | Xolair | $600 | 1 payment
|
| Genentech | Xolair | $222 | 2 payments
|
2022: $2,854
| Genentech | Xolair | $2,245 | 2 payments
|
| Regeneron Pharmaceuticals | Dupixent | $575 | 1 payment
|
| Genentech USA | Xolair | $34 | 1 payment
|
2020: $389
| AstraZeneca Pharmaceuticals LP | None | $389 | 1 payment
|
2019: $22
| GlaxoSmithKline | Nucala | $22 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| AIMMUNE THERAPEUTICS, INC. · A Multicenter, Open-Label, Long-Term Safety Study of Ar101 Characterized Oral Desensitization Immunotherapy in Subjects Who Participated in A Prior Ar101 Study · 2022 | Their institution | $123,494 |
| Regeneron Pharmaceuticals, Inc. · A Phase 3, Randomized, 3-Part Study To Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (Eoe) · 2020 | Their institution | $119,761 |
| Regeneron Pharmaceuticals, Inc. · A Study To Evaluate the Efficacy and Safety of Dupilumab Monotherapy in Pediatric Patients With Peanut Allergy · 2021 | Their institution | $112,595 |
| Regeneron Pharmaceuticals, Inc. · A Phase 3, Randomized, 3-Part Study To Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis Eoe · 2019 | Their institution | $97,592 |
| AIMMUNE THERAPEUTICS, INC. · Peanut Oral Immunotherapy Study of Early Intervention for Desensitization (Poseidon) · 2020 | Their institution | $85,733 |
| AIMMUNE THERAPEUTICS, INC. · Peanut Oral Immunotherapy Study of Early Intervention for Desensitization (Poseidon) · 2021 | Their institution | $80,881 |
| Regeneron Pharmaceuticals, Inc. · A Phase 3, Randomized, 3-Part Study To Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (Eoe) · 2021 | Their institution | $69,842 |
| Regeneron Pharmaceuticals, Inc. · A Phase 3, Randomized, 3-Part Study To Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (Eoe) · 2022 | Their institution | $44,059 |
| Regeneron Pharmaceuticals, Inc. · A Study To Evaluate the Efficacy and Safety of Dupilumab Monotherapy in Pediatric Patients With Peanut Allergy · 2020 | Their institution | $29,073 |
| Regeneron Pharmaceuticals, Inc. · A Phase 3, Randomized, 3-Part Study To Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (Eoe) · 2023 | Their institution | $26,328 |
| Regeneron Pharmaceuticals, Inc. · A Study To Evaluate the Efficacy and Safety of Dupilumab Monotherapy in Pediatric Patients With Peanut Allergy · 2019 | Their institution | $14,524 |
| Novartis Pharmaceuticals Corporation · A Two Treatment Epoch Randomized Placebo Controlled Multi Centered Parallel Group Study To Assess the Safety of Qaw039 When Added To Existing Asthma Therapy in Patients With Uncontrolled Severe Asthma · 2019 | Their institution | $7,000 |
| SANOFI US SERVICES INC. · A Randomized, Multicenter, 3-Arm, Double-Blind, Placebo-Controlled Study To Assess the Safety, Tolerability and Pharmacodynamics of Repeated Sublingual Daily Administration of Sar439794 in Peanut Alle · 2019 | Their institution | $6,901 |
| AIMMUNE THERAPEUTICS, INC. · 2024 | Their institution | $6,861 |
| SANOFI US SERVICES INC. · A Randomized, Multicenter, 3-Arm, Double-Blind, Placebo-Controlled Study To Assess the Safety, Tolerability and Pharmacodynamics of Repeated Sublingual Daily Administration of Sar439794 in Peanut Allergic Adult Patients · 2020 | Their institution | $5,657 |
| Novartis Pharmaceuticals Corporation · A Two Treatment Epoch Randomized Placebo Controlled Multi Centered Parallel Group Study To Assess the Safety of Qaw039 When Added To Existing Asthma Therapy in Patients With Uncontrolled Severe Asthma · 2020 | Their institution | $5,560 |
| SANOFI US SERVICES INC. · A Randomized, Multicenter, 3-Arm, Double-Blind, Placebo-Controlled Study To Assess the Safety, Tolerability and Pharmacodynamics of Repeated Sublingual Daily Administration of Sar439794 in Peanut Allergic Adult Patients · 2019 | Their institution | $3,419 |
| Novartis Pharmaceuticals Corporation · A 52 Week, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Assess the Clinical Efficacy and Safety of Ligelizumab (Qge031) in Decreasing the Sensitivity To Peanuts in Patients With Peanut Allergy · 2023 | Their institution | $428 |
| Novartis Pharmaceuticals Corporation · A 52 Week, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Assess the Clinical Efficacy and Safety of Ligelizumab (Qge031) in Decreasing the Sensitivity To Peanuts in Patients With Peanut Allergy · 2022 | Their institution | $402 |
| Novartis Pharmaceuticals Corporation · A 52 Week, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Assess the Clinical Efficacy and Safety of Ligelizumab (Qge031) in Decreasing the Sensitivity To Peanuts in Patients With Peanut Allergy · 2024 | Their institution | $26 |
| AIMMUNE THERAPEUTICS, INC. · A Multicenter, Open-Label, Long-Term Safety Study of Ar101 Characterized Oral Desensitization Immunotherapy in Subjects Who Participated in A Prior Ar101 Study · 2021 | Their institution | $21 |
Professional record
- NPI
- 1366739740
- Licence
- CA A144981, PA MD448254California A144981: Current · expires 2028-01-31
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207K00000X (207K00000X); Pediatrics (208000000X)
- Mailing address
- 725 Welch Rd, Palo Alto, CA, 94304
- NPI first listed
- 2011-07-06
- NPI last updated
- 2024-04-16
- NPI record certified
- 2024-04-16
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1804 Embarcadero Rd, Palo Alto, CA, 94303 · 300 Pasteur Dr, Stanford, CA, 94305